肝臓移植:治療薬開発パイプライン動向(2014年下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5261IDB)
◆英語タイトル:Liver Transplantation - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5261IDB
◆発行日:2014年7月31日
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[肝臓移植:治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Liver Transplantation – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Liver Transplantation – Pipeline Review, H2 2014’, provides an overview of the Liver Transplantation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Liver Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Liver Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Transplantation Overview 7
Therapeutics Development 8
Pipeline Products for Liver Transplantation – Overview 8
Pipeline Products for Liver Transplantation – Comparative Analysis 9
Liver Transplantation – Therapeutics under Development by Companies 10
Liver Transplantation – Therapeutics under Investigation by Universities/Institutes 12
Liver Transplantation – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Liver Transplantation – Products under Development by Companies 16
Liver Transplantation – Products under Investigation by Universities/Institutes 17
Liver Transplantation – Companies Involved in Therapeutics Development 18
Astellas Pharma Inc. 18
Veloxis Pharmaceuticals A/S 19
Digna Biotech, S.L. 20
Conatus Pharmaceuticals Inc. 21
Dompe Farmaceutici S.p.A. 22
Isogenis, Inc. 23
Kings College London 24
Liver Transplantation – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
tacrolimus – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tacrolimus ER – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
reparixin – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
emricasan – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cell Therapy for Liver Transplantation – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Stem Cell Therapy for Immunology and Gastrointestinal Disorders – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
cardiotrophin-1 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Allogenic T regs – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Cell Therapy for Liver Transplantation – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ABC-294640 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Liver Transplantation – Recent Pipeline Updates 54
Liver Transplantation – Dormant Projects 65
Liver Transplantation – Discontinued Products 66
Liver Transplantation – Product Development Milestones 67
Featured News & Press Releases 67
May 22, 2014: Veloxis Receives Positive Opinion from CHMP for Envarsus for Treatment of Both Kidney and Liver Transplant Patients 67
May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 68
Apr 28, 2014: Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus in Liver Transplant Patients 68
Jan 08, 2014: Veloxis Pharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Diurnal-Independent Administration of Envarsus 69
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan’s Safety Profile at the AASLD Liver Meeting 69
Sep 04, 2013: Phase III Clinical Study Data Demonstrating LCP-Tacro’s Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation 70
Aug 22, 2013: Drug Application Filed for Additional Form of Immunosuppressant, “Cellcept Powder for Oral Suspension 32%” 72
Feb 15, 2013: Novartis’s Zortress Receives FDA Approval To Prevent Organ Rejection In Adult Liver Transplant Patients 72
Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 73
Nov 12, 2012: Novartis Announces Positive Outcomes From Phase III Study Of Certican In Liver Transplantation 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products under Development for Liver Transplantation, H2 2014 8
Number of Products under Development for Liver Transplantation - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Liver Transplantation - Pipeline by Astellas Pharma Inc., H2 2014 18
Liver Transplantation - Pipeline by Veloxis Pharmaceuticals A/S, H2 2014 19
Liver Transplantation - Pipeline by Digna Biotech, S.L., H2 2014 20
Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 21
Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 22
Liver Transplantation - Pipeline by Isogenis, Inc., H2 2014 23
Liver Transplantation - Pipeline by Kings College London, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Liver Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 54
Liver Transplantation - Dormant Projects, H2 2014 65
Liver Transplantation - Discontinued Products, H2 2014 66

List of Figures
Number of Products under Development for Liver Transplantation, H2 2014 8
Number of Products under Development for Liver Transplantation - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Top 10 Target, H2 2014 26
Number of Products by Stage and Top 10 Target, H2 2014 27
Number of Products by Top 10 Mechanism of Action, H2 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 30
Number of Products by Top 10 Route of Administration, H2 2014 32
Number of Products by Stage and Top 10 Route of Administration, H2 2014 33
Number of Products by Top 10 Molecule Type, H2 2014 34
Number of Products by Stage and Top 10 Molecule Type, H2 2014 35

*** 掲載企業 ***

Astellas Pharma Inc.
Veloxis Pharmaceuticals A/S
Digna Biotech, S.L.
Conatus Pharmaceuticals Inc.
Dompe Farmaceutici S.p.A.
Isogenis, Inc.
Kings College London

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5261IDB )"肝臓移植:治療薬開発パイプライン動向(2014年下半期)" (英文:Liver Transplantation - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。